Booming market of Single-use bioprocessing market growth factors, key players, and regional analysis

Single-use systems are items used to manufacture biopharmaceuticals that are discarded after a single use. Single-use systems frequently consist of plastic parts that have undergone gamma irradiation to sterilize and seal them.


In 2021, the market for single-use bioprocessing was worth USD 14.83 billion, and by 2030 it will reach USD 55.78 billion, growing at a 15.86% CAGR during the forecast period.


The rising rate of chronic disorders globally is one of the primary factors boosting the market growth. They are the world’s most fatal killers, responsible for more than 63% of all deaths. The market for single-use bioprocessing will benefit from expanding clinical research activities to understand the potential of biotherapeutics against various disease areas.


Market Dynamics




Increased private investments and an expanding presence of supportive government policies are boosting the development of vaccines and biologics by major companies. For instance, China and India have the highest market potential in the Asia Pacific region for single-use bioprocessing systems. The availability of a competent workforce in Asian nations and the steadily expanding geriatric population are boosting market growth.


The rising geriatric population in North America is the cause of the rising demand for biopharmaceuticals and the benefits of single-use bioprocessing. Single-use bioprocessing market expansion is encouraged by benefits like high energy efficiency, low water usage, fewer footprint requirements, lower installation costs, reduced cross-contamination, and quick deployment




The market for single-use bioprocessing is constrained by issues with extractability related to plastic bag disposal and potential environmental harm. Moreover, a big commercial challenge is the waste management of single-use procedures.




China and India are the two countries in the Asia-Pacific area with the highest potential markets for single-use bioprocessing systems. This is due to favorable government policies, increased private investment, an aging population, a marked increase in outsourcing to developing Asian markets, and skilled labor in these countries. The significant investment in bio-manufacturing infrastructure is also a key factor in these industries’ excellent development potential.


Market Segmentation 


By Product


The simple & peripheral elements segment led the market in 2022 with 49.1% of the revenue share. It is due to ongoing product improvements and the growing importance of bioprocessing operations in production. For instance, improvements in the single-use system have compelled engineers of bioprocesses to substitute single-use transfer lines for permanent pipe networks. Market participants can take advantage of untapped market prospects and increase their market positions thanks to the availability of disposable bioprocess bags in various sizes for a range of applications.


By Workflow


In 2022, the upstream bioprocessing segment ruled the market with the highest share of 57.9%. This is due to the ongoing improvements and advances in upstream bioprocessing technology. For instance, cutting-edge technologies like the Ambr 15 micro-bioreactor system from Sartorius AG offer automated experimental setup and sampling in addition to high-throughput upstream process development, efficient cell culture processing, and media & feed optimization.


By End-Use


Manufacturers of biopharmaceuticals ruled the market, with the largest share of 58.1% in 2022. The segment is expanding due to rising contract manufacturing and research services as well as an increase in the commercial success of biologics in recent years. In bioprocessing operations, CROs and CMOs can provide several advantages, including scalability, flexibility, a reduction in the need for internal infrastructure, and dedicated supply channels. These benefits encourage the use of contract services and are projected to have a favorable impact on the sector’s expansion in the near future.


Regional Overview 


North America was the market leader, with a revenue share of 34.2% in 2022. It is due to the region’s established pharmaceutical and biomanufacturing sector and extensive R&D efforts. A growing emphasis on vaccine production drives the need for single-use bioprocessing equipment to support local efforts at disease prevention. Furthermore, the Bio-process System Alliance (BPSA) in North America, which aims to advance the adoption of single-use technologies, will drive disposable system sales in the region.


The Asia Pacific region will develop at the fastest rate, 16.71%. Several investments from numerous international corporations have been made in the region’s expanding bioprocessing market. These investments help important businesses establish a regional presence and seize unexplored opportunities.


Key Players 


  • Avantor
  • Sartorius Stedim Biotech S.A.
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Merck KGaA
  • Getinge AB
  • Corning
  • Eppendorf AG
  • Entegris
  • Cellexus
  • CESCO Bioengineering Co. Ltd.
  • PBS Biotech, Inc.
  • OmniBRx Biotechnologies
  • ABEC, Inc.
  • Distek, Inc.
  • G&G Technologies
  • Able Corporation & Biott Corporation
  • Stobbe Pharma GmbH
  • Solida Biotech GmbH
  • Satake Chemical Equipment Mfg., Ltd.
  • Celltainer Biotech
  • Bbi-Biotech GmbH
  • Meissner Filtration Products, Inc.
  • Catalent
  • Pierre Guerin
  • Kuhner AG


In 2021, the market for single-use bioprocessing was worth USD 14.83 billion, and by 2030 it will reach USD 55.78 billion, growing at a 15.86% CAGR during the forecast period. The single-use bioprocessing market is driven by faster implementation, less risk of product cross-contamination, rising demand for biopharmaceuticals, lower pricing, and fewer negative environmental effects.

Such a progressing and nonstop expansion in the reception of these bioprocessing frameworks because of the Coronavirus pandemic is expected to drive industry development. The business outcome of biopharmaceuticals has driven single-use makers to around the world extend their creation offices. Limit extension projects have been a piece of many producers’ long term plans, to use a worldwide reach and a more extensive client base. For example, in December 2020, Merck KGaA contributed over USD 42 million to widen its current assembling offices in Danvers, Massachusetts, and Jaffrey, New Hampshire, U.S.

This development was pointed toward upgrading the organization’s single-use gathering tasks alongside other item portfolios. Besides, with the rising spotlight on the improvement of regenerative medication, like cell and quality treatments, expanded outcome of clinical preliminaries, and upgraded pace of administrative endorsements, interest for commercialization of these items is supposed to fill sooner rather than later. Also, attributable to the expanding reevaluating exercises in biopharmaceutical fabricating, CMOs are taking on single-use frameworks for keeping up with exceptionally powerful and much of the time changing item portfolios.

Related Reports:

Endoscopy Devices Market Report – The global endoscopy devices market will witness a robust CAGR of 7.1%, valued at $30.3 billion in 2021, expected to appreciate and reach $56.2 billion by 2030, confirms Strategic Market Research. North America had the greatest revenue share of 42.3 % in the market in 2021.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top